Archive for November 2022
A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables.
Fu Y., Guo T., Taghvafard H., Said M.M., Demeester C., Dudal V., Graaf van der P.H., Snelder N., Hasselt van C.J.G. A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables. PAGE 2022 [Link to publication]
Read MoreFinerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
Berg van der P., Ruppert M., Mesic E., Snelder N., Seelmann A., Heinig R., Joseph A., Garmann D., Lippert J., Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. PAGE 2022. [Link to publication]
Read MoreLinking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity.
Bosch R., Snelder N. Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity. ACoP 2022. [Link to publication]
Read MorePopulation pharmacokinetics of daprodustat across five phase 2b/3 studies in chronic kidney disease (CKD) patients with anemia.
Mahar K.M., Goulooze S.C., Yang S., Mesic E., Beerahee M., Post T.M. Population pharmacokinetics of daprodustat across five phase 2b/3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Read MorePopulation Dose-Hgb modelling of daprodustat across five Phase 3 studies in chronic kidney disease (CKD) patients with anemia.
Noort van N., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population Dose-Hgb modelling of daprodustat across five Phase 3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Read MoreInnovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population doe-hemoglobin model for daprodustat.
Goulooze S.C., Noort van N., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population doe-hemoglobin model for daprodustat. ACoP 2022. Link to publication
Read More